论文部分内容阅读
目的:探讨雌激素受体(ER)和表皮生长因子受体(EGFR)在分化型甲状腺癌(DTC)中的表达及其意义。方法:用免疫组化SP法检测45例(DTC)组织中ER和EGFR的表达。结果:ER在DTC组中的阳性率为37.3%,明显高于良性腺瘤和正常组(P<0.05);EGFR在DTC组中的阳性率为57.7%,明显高于两对照组(P<0.05)。ER在DTC中的表达与性别和年龄有关;EGFR的表达与DTC中的淋巴结转移有关。结论:ER和EGFR的表达可以作为鉴别甲状腺肿瘤良恶性的指标EGFR可作为甲状腺癌患者预后的指标。
Objective: To investigate the expression of estrogen receptor (ER) and epidermal growth factor receptor (EGFR) in differentiated thyroid carcinoma (DTC) and its significance. Methods: The expressions of ER and EGFR in 45 cases (DTC) tissues were detected by immunohistochemical SP method. Results: The positive rate of ER in DTC group was 37.3%, which was significantly higher than that in benign adenoma group and normal group (P <0.05). The positive rate of EGFR in DTC group was 57.7%, which was significantly higher than that in the two control groups (P < 0.05). The expression of ER in DTC is related to gender and age. The expression of EGFR is related to lymph node metastasis in DTC. Conclusion: The expression of ER and EGFR can be used as an index to differentiate benign and malignant thyroid neoplasms. EGFR can be used as an index of prognosis in patients with thyroid carcinoma.